BioHarvest Sciences (NASDAQ:BHST) Shares Down 0.7% – What’s Next?

Shares of BioHarvest Sciences Inc. (NASDAQ:BHST) fell 0.7% on Thursday . The company traded as low as $2.76 and last traded at $2.83. Approximately 52,994 shares traded hands during trading, an increase of 79% from the average session volume of 29,619 shares. The stock had previously closed at $2.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

BioHarvest Sciences Stock Down 0.7%

The company has a debt-to-equity ratio of 0.03, a current ratio of 2.96 and a quick ratio of 2.44. The firm’s 50-day simple moving average is $3.33 and its two-hundred day simple moving average is $4.17. The company has a market capitalization of $55.52 million, a price-to-earnings ratio of -4.80 and a beta of 0.87.

BioHarvest Sciences (NASDAQ:BHST) last issued its earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%. The company had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $8.50 million. Sell-side analysts predict that BioHarvest Sciences Inc. will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On BioHarvest Sciences

Several hedge funds have recently bought and sold shares of BHST. Alyeska Investment Group L.P. acquired a new position in BioHarvest Sciences during the fourth quarter worth $3,929,000. Thompson Siegel & Walmsley LLC acquired a new stake in BioHarvest Sciences in the fourth quarter valued at $1,945,000. Evercore Wealth Management LLC acquired a new stake in BioHarvest Sciences in the fourth quarter valued at $724,000. True North Advisors LLC increased its position in shares of BioHarvest Sciences by 381.0% in the first quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock valued at $729,000 after buying an additional 133,085 shares in the last quarter. Finally, King Luther Capital Management Corp purchased a new position in shares of BioHarvest Sciences in the fourth quarter valued at $208,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.